# A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients

> **NCT04352595** · PHASE2 · COMPLETED · sponsor: **Tianjin Hemay Pharmaceutical Co., Ltd** · enrollment: 148 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Hemay808

## Key facts

- **NCT ID:** NCT04352595
- **Lead sponsor:** Tianjin Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-24
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-04-02
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04352595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04352595, "A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04352595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*